These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 39031388)

  • 1. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.
    McFarthing K; Buff S; Rafaloff G; Pitzer K; Fiske B; Navangul A; Beissert K; Pilcicka A; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2024; 14(5):899-912. PubMed ID: 39031388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.
    McFarthing K; Buff S; Rafaloff G; Fiske B; Mursaleen L; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2023; 13(4):427-439. PubMed ID: 37302040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.
    McFarthing K; Rafaloff G; Baptista M; Mursaleen L; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2022; 12(4):1073-1082. PubMed ID: 35527571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.
    McFarthing K; Rafaloff G; Baptista MAS; Wyse RK; Stott SRW
    J Parkinsons Dis; 2021; 11(3):891-903. PubMed ID: 34151864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
    McFarthing K; Buff S; Rafaloff G; Dominey T; Wyse RK; Stott SRW
    J Parkinsons Dis; 2020; 10(3):757-774. PubMed ID: 32741777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.
    Wyse RK; Isaacs T; Barker RA; Cookson MR; Dawson TM; Devos D; Dexter DT; Duffen J; Federoff H; Fiske B; Foltynie T; Fox S; Greenamyre JT; Kieburtz K; Kordower JH; Krainc D; Matthews H; Moore DJ; Mursaleen L; Schwarzschild MA; Stott SRW; Sulzer D; Svenningsson P; Tanner CM; Carroll C; Simon DK; Brundin P
    J Parkinsons Dis; 2024; 14(4):657-666. PubMed ID: 38578902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of disease-modifying drugs for Parkinson's disease. Is it a tough road?].
    Nagai M
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):223-227. PubMed ID: 36990797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amantadine in Parkinson's disease.
    Crosby N; Deane KH; Clarke CE
    Cochrane Database Syst Rev; 2003; 2003(1):CD003468. PubMed ID: 12535476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive Effects of Three β-Adrenoceptor Acting Drugs in Healthy Volunteers and Patients with Parkinson's Disease.
    Eijsvogel PPNM; Borghans LGJM; Prins S; Moss L; van Kraaij SJW; van Brummelen E; Klaassen E; Martin RS; Bautista E; Ford AP; Kremer PHC; Groeneveld GJ; Vargas GA
    J Parkinsons Dis; 2024; 14(6):1149-1161. PubMed ID: 39213090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
    Carroll CB; Webb D; Stevens KN; Vickery J; Eyre V; Ball S; Wyse R; Webber M; Foggo A; Zajicek J; Whone A; Creanor S
    BMJ Open; 2019 Oct; 9(10):e029740. PubMed ID: 31594876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
    Grover ND; Limaye RP; Gokhale DV; Patil TR
    Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease?
    Lenka A; Jankovic J
    Expert Rev Neurother; 2023 Feb; 23(2):107-122. PubMed ID: 36803618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease.
    McGhee DJ; Ritchie CW; Zajicek JP; Counsell CE
    BMC Neurol; 2016 Jun; 16():92. PubMed ID: 27312378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
    Seppi K; Weintraub D; Coelho M; Perez-Lloret S; Fox SH; Katzenschlager R; Hametner EM; Poewe W; Rascol O; Goetz CG; Sampaio C
    Mov Disord; 2011 Oct; 26 Suppl 3(0 3):S42-80. PubMed ID: 22021174
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.